The Safety of Opioid Use in Chronic Obstructive Pulmonary Disease
The Safety of Opioid Use in Chronic Obstructive Pulmonary Disease
May’s Journal Club features a study discussing the association between transient opioid use and short-term respiratory exacerbation in patients with COPD. Learn the pros and cons related to clinical outcomes and safety, as discussed in the GOLD Guidelines and other documented trials.
Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Discuss existing guidelines for treatment of dyspnea among patients with Chronic Obstructive Pulmonary Disease (COPD)
2. Evaluate the strengths of evidence from various existing studies
3. Interpret the findings of Rong et al., 2019 and draw conclusions for clinical practice
4. Describe the applicability, strengths, and limitations of case-crossover designs
5. Identify avenues for future research to improve our understanding of opioid use among patients with COPD
Sujith Ramachandran, PhD
Assistant Professor
University of Mississippi School of Pharmacy
Sujith Ramachandran does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course.
To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:
Rong Y, Bentley JP, McGwin G, et al, Association Between Transient Opioid Use and Short-Term Respiratory Exacerbation Among Adults With Chronic Obstructive Pulmonary Disease: A Case-Crossover Study, American Journal of Epidemiology, Volume 188, Issue 11, November 2019, Pages 1970–1976, https://doi.org/10.1093/aje/kwz169. Available at: https://academic.oup.com/aje/article/188/11/1970/5540805?login=true
*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.
This course is included in our Pharmacist Membership. To get more courses like this every month, sign-up!
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: May 12, 2021
Planned Expiration Date: May 12, 2024
RV3-2.24/EXP
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
| Duration | 1h 0m |
|---|---|
| Topic Designator | Disease State/Drug Therapy |
| ACPE | Yes |
| ACPE Topic | 01 Drug Therapy |
| Role | Pharmacist |
| Media-Type | On-Demand |
| Release Date | 5/12/21 |
| CEUs | 0.1 |
| Rating | 4 |
| ACPE Number | 0107-0000-21-179-H01-P |
